Pfizer: Oncology Breakthroughs, GLP-1 Weight Management and Strategic M&A Insights with CFO David Denton

In the latest episode of After Earnings, Pfizer CFO David Denton shares insights into the company’s achievements and future strategies with Ann Berry and Katie Perry. They discuss topics like acquiring Seagen, the use of AI in drug development, and ongoing initiatives in oncology and weight management. Denton addresses shareholder concerns about financial performance, emphasizing Pfizer’s dedication to innovation through significant investments in M&A and R&D. He also highlights the development of an oral GLP-1 receptor for obesity management and efforts to maintain robust dividends.

$PFE

00:00 START

00:55 Pfizer’s Current Position and Achievements

02:23 Strategic Acquisitions and Investments

06:04 AI and Digital Transformation in Drug Development

08:33 New Product Development: Oral Semaglutide

10:37 Challenges and Market Opportunities

15:39 Direct-to-Consumer Strategies and M&A

20:31 Investor Relations and Future Outlook

After Earnings is brought to you by Stakeholder Labs and Morning Brew.

For more go to https://www.afterearnings.com

Follow Us

X: https://twitter.com/AfterEarnings  

TikTok: https://www.tiktok.com/@AfterEarnings  

Instagram: https://www.instagram.com/afterearnings_ / 

Reach Out

Email: afterearnings@morningbrew.com

Learn more about your ad choices. Visit megaphone.fm/adchoices